ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

DCPC Bard Approves Concepts For New Grant Programs

November 13, 1992

Key Cancer Legislation Remains Unfinished as Congress Departs for Election.

October 6, 2006

FDA Proposes To Require Electronic Submission

May 3, 2002

DeVita To continue Discussions On Expanded Chops Despite ACCC Coolness; Would Go To DRCCA Board

March 27, 1981

DCE Advisors Okay Contract Recompetitions For Epidemiology

November 18, 1994

ASCO Releases Three Guidelines For Cancer Survivorship Care

April 25, 2014